The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Choline PET or PET/CT and Biochemical Relapse of Prostate Cancer: A Systematic Review and Meta-Analysis
Open accessAbstract
AIM: The increase of prostate-specific antigen (PSA) after radical retropubic prostatectomy (RP) or external beam radiotherapy (EBRT) is the most sensitive tool for detecting prostate cancer (PCa) recurrence, although this measure cannot distinguish between local, regional, or distant recurrence. The aim of this meta-analysis was to evaluate the diagnostic performance of 18F-choline and 11C-choline PET or PET/CT in detection of locoregional or distant metastases in PCa. MATERIALS AND METHODS: Medline, Web of Knowledge, and Google Scholar search was carried out in order to select English-language articles dealing with diagnostic performance of both 18F-choline and 11C-choline PET for the detection of PCa recurrence after RP or EBRT. Articles were included only if absolute numbers of true-positive, true-negative, false-positive, and false-negative test results were available or derivable from the text and regarded local, lymph node, and distant metastases. Reviews, clinical reports, and editorial articles were excluded. All complete studies were re-analyzed thus performing a quantitative analysis. RESULTS: From the years 2000 to 2012, we found 53 complete articles that critically evaluated the role of choline PET in restaging patients with PCa recurrence. The meta-analysis was carried out and dealt with 19 selected studies (12 studies for all sites of disease, 3 for lymph node metastases, and 4 for local recurrence), with a total of 1555 patients. The meta-analysis provided a pooled sensitivity of 85.6% (95% CI: 82.9%-88.1%) and pooled specificity of 92.6% (95% CI: 90.1%-94.6%) for all sites of disease (prostatic fossa, lymph nodes, and bone), a pooled sensitivity of 75.4% (95% CI: 66.9%-82.6%) and pooled specificity of 82% (95% CI: 68.6%-91.4%) for prostatic fossa recurrence, and a pooled sensitivity of 100% (95% CI: 90.5%-100%) and pooled specificity of 81.8% (95% CI: 48.2%-97.7%) for lymph node metastases. The heterogeneity ranged between 0.00% and 88.6%. The diagnostic odds ratios were 62.123 (95% CI: 24.783-155.72), 5.869 (95% CI: 1.818-18.946), and 138.57 (95% CI: 11.27-1703.8), respectively, for all sites of disease, local recurrence, and lymph node disease. CONCLUSIONS: Choline PET and PET/CT represent high sensitivity and specificity techniques for the detection of locoregional and distant metastases in PCa patients with recurrence of disease. Moreover, a high diagnostic odds ratio was found for the identification of lymph node disease in patients with biochemical recurrence of PCa.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Whiting, P., Rutjes, A. W., Reitsma, J. B., Bossuyt, P. M., & Kleijnen, J. (2003) · BMC Medical Research Methodology · doi:10.1186/1471-2288-3-25 · Cited by 3,592
Meta-DiSc: a software for meta-analysis of test accuracy data
Zamora, J., Abraira, V., Muriel, A., Khan, K., & Coomarasamy, A. (2006) · BMC Medical Research Methodology · doi:10.1186/1471-2288-6-31 · Cited by 1,883
Adjuvant Radiotherapy for Pathologically Advanced Prostate Cancer: A Randomized Clinical Trial
Thompson, I. M., Tangen, C. M., Paradelo, J., Lucia, M. S., Miller, G., Troyer, D., Messing, E., Forman, J., Chin, J., Swanson, G., et al. (2006) · JAMA · doi:10.1001/jama.296.19.2329 · Cited by 897
EAU Guidelines on Prostate Cancer
Aus, G., Abbou, C. C., Bolla, M., Heidenreich, A., Schmid, H.-P., van Poppel, H., Wolff, J., & Zattoni, F. (2005) · European Urology · doi:10.1016/j.eururo.2005.06.001 · Cited by 579
Self-citationDoes blinding of readers affect the results of meta-analyses?
Berlin, J. A. (1997) · The Lancet · doi:10.1016/s0140-6736(05)62352-5 · Cited by 478
Krause, B. J., Souvatzoglou, M., Tuncel, M., Herrmann, K., Buck, A. K., Praus, C., Schuster, T., Geinitz, H., Treiber, U., & Schwaiger, M. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0581-4 · Cited by 367
Cimitan, M., Bortolus, R., Morassut, S., Canzonieri, V., Garbeglio, A., Baresic, T., Borsatti, E., Drigo, A., & Trovò, M. G. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0150-2 · Cited by 312
Evaluation of [18F]-choline PET/CT for staging and restaging of prostate cancer
Husarik, D. B., Miralbell, R., Dubs, M., John, H., Giger, O. T., Gelet, A., Cservenyàk, T., & Hany, T. F. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0552-9 · Cited by 295
Prostate Cancer: PET with 18F-FDG, 18F- or 11C-Acetate, and 18F- or 11C-Choline
Jadvar, H. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.077941 · Cited by 290
Cited by
Positron Emission Tomography (PET) in Oncology
Gallamini, A., Zwarthoed, C., & Borra, A. (2014) · Cancers · doi:10.3390/cancers6041821 · Cited by 312
Rowe, S. P., Macura, K. J., Mena, E., Blackford, A. L., Nadal, R., Antonarakis, E. S., Eisenberger, M., Carducci, M., Fan, H., Dannals, R. F., et al. (2016) · Molecular Imaging and Biology · doi:10.1007/s11307-016-0957-6 · Cited by 258
A urologist’s perspective on prostate cancer imaging: past, present, and future
George, A. K., Turkbey, B., Valayil, S. G., Muthigi, A., Mertan, F., Kongnyuy, M., & Pinto, P. A. (2016) · Abdominal Radiology · doi:10.1007/s00261-016-0751-6 · Cited by 30
Metadata
- Authors
- Evangelista, L., Zattoni, F., Guttilla, A., Saladini, G., Zattoni, F., Colletti, P. M., & Rubello, D.
- Venue
- Clinical Nuclear Medicine
- Published
- 2013-05
- Volume
- 38
- Issue
- 5
- Pages
- 305-314
- ISSN
- 0363-9762 (ISSN-L)
- OpenAlex
- W1995205917
- Cited by
- 278
- References
- 28
- FWCI
- 24.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Choline PET or PET/CT and Biochemical Relapse of Prostate Cancer: A Systematic Review and Meta-Analysis. https://app.cochat.ai/papers/10.1097/rlu.0b013e3182867f3c
- The paper
- Evangelista, L., Zattoni, F., Guttilla, A., Saladini, G., Zattoni, F., Colletti, P. M., & Rubello, D. (2013). Choline PET or PET/CT and Biochemical Relapse of Prostate Cancer: A Systematic Review and Meta-Analysis. Clinical Nuclear Medicine. https://doi.org/10.1097/rlu.0b013e3182867f3c
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.